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Abstract
To establish the contribution of TP53 germline mutations to familial breast/ovarian cancer in Germany we
screened the complete coding region of the TP53 gene in a series of German breast/ovarian cancer families
negative for mutations in the BRCA1 and BRCA2 genes. 
Two different intronic TP53 sequence variants were identified in 6/48 (12.5%) breast/ovarian cancer families.
A novel A to T nucleotide change at position 17708 in intron 10 segregating with the disease was detected in
three breast cancer families (6.2%). One 17708 A>T-associated breast tumour showed loss of the wild-type
allele. This variant was also found in 5/112 (4.5%) healthy controls indicating that it is a polymorphism. A second
sequence variant changing a G to C at position 13964 in intron 6 not segregating with the disease was found
in two breast cancer families and one breast-ovarian cancer family (6.2%). This variant has previously been
shown to occur at an elevated frequency in hereditary breast cancer patients from North America and to be of
functional importance leading to inhibition of apoptosis and prolongation of cell survival after DNA-damage.
Screening of 185 consecutive unselected German breast cancer patients revealed the 13964 G>C variant in
four patients (2.2%). Immunohistochemical analysis of the TP53 protein showed negative immunoreactivity in
normal and tumour tissues of one 17708 A>T and six 13964 G>C carriers. TP53 overexpression was detected
in the tumour tissue of one sporadic breast cancer patient carrying the 13964 G>C variant. Our results show
that intronic changes of the TP53 gene may act as or be associated with risk modifiers in familial breast cancer. 
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Introduction
Breast cancer is the most common malignancy and
the leading cause of cancer mortality among women
worldwide [1]. Approximately 5-10% of breast and
ovarian cancer cases are due to an inherited
susceptibility. The majority of these are due to germline
mutations in the BRCA1 and BRCA2 genes [2-5].
However, other genes responsible for inherited
susceptibility to breast and/or ovarian cancer have been
identified, including TP53, PTEN, and ATM [6]. 
TP53 germline mutations have been found in the
majority of families with the Li-Fraumeni syndrome
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(LFS), which is characterized by a large spectrum of
different tumour types usually arising at an early age
[7, 8]. Mutations were also found in Li-Fraumeni-like
families (LFL) and in about 1% of breast/ovarian cancer
families [9-14]. 
The majority of TP53 germline mutations are
missense mutations that are most often localised to the
conserved exons [15]. Since one third of LFS patients
do not harbour detectable TP53 exon mutations, other
mutations located in intron and promoter sites could
exist, which may be important in regulating gene
expression. A few intronic TP53 mutations that result
in aberrant gene expression have been identified [16,
17]. Recently a specific intronic TP53 13964 G>C
germline mutation with functional activity was found at
an elevated frequency in North-American hereditary
breast cancer patients [18]. 
In Germany, germline mutations in BRCA1 and
BRCA2 account for about 30% of hereditary
breast/ovarian cancer families [19-23]. As a substantial
proportion of German breast/ovarian families are
negative for BRCA1 and BRCA2 germline mutations,
we screened the complete coding region of the TP53
gene in a series of 48 breast/ovarian cancer families
deemed negative for mutations in both genes. Mutation
analysis was performed using a combination of single
strand conformational polymorphism analysis (SSCP)
followed by DNA sequence analysis. 
Methods
Breast cancer patients
Hereditary breast cancer patients were identified
through an ongoing research family study of hereditary
breast and/or ovarian cancer which recruits families
from all over Germany. Families containing three or
more members affected with breast/ovarian cancer
with at least two breast cancer cases diagnosed under
the age of 60 and ovarian cancer diagnosed at any
age were ascertained through gynaecologists or in
response to press publicity in Germany. Each pedigree
was extended through an index case and available
related family members. 
One hundred and eighty-five unselected consecutive
breast cancer patients were recruited from the Städtisches
Klinikum Karlsruhe between the years 1998 and 1999.
All participants gave informed consent prior to donating
blood samples. All cancer cases were verified by
pathology reports. 
Forty-eight German breast and/or ovarian cancer
families negative for BRCA1 and BRCA2 germline
mutations were included in this study. Forty-three families
were described previously [19-22, 24]. Five families not
described in the referenced studies were recently
identified and analysed for BRCA1 and BRCA2 mutations
(U. Hamann, unpublished results) from which one
missense change was identified (see below). According
to the definitions by Birch et al [25], none of the families
fulfilled the definition for LFS or LFL families. 
TP53 mutation analysis
The entire TP53 coding region (Genbank accession
number U94788) and the splice junctions were analysed
using PCR-based single strand conformation
polymorphism analysis (SSCP), followed by DNA
sequencing analysis of all unusual conformers. PCR,
primer pairs and cycling conditions were as described
[26, 27]. Amplified samples were diluted 1:10 in
formamide buffer (98% formamide, 10 mM EDTA pH 8,
0.05% bromophenol blue, 0.05% xylene cyanol), heated
to 95°C for 5 min. and chilled in ice for 5 min. Three to
five µl of this mixture were loaded on to 0.6 x MDE gels
(FMC Biochemicals) and run at 6 W constant power for
7-16 hours in 0.6 x TBE at room temperature. Variant
bands were detected by autoradiography. Any sample
revealing a variant band on SSCP gels was sequenced
on a CEQ 2000 DNA sequencer (Beckman) according
to the manufacturers’ instructions or on an ABI model
370 automated DNA sequencer (Perkin Elmer). Both
forward and reverse strands of genomic DNA were
sequenced to confirm the presence of a mutation. 
DNA samples from the 185 breast cancer patients
unselected for family history were screened for the
13964 G>C mutation in intron 6 by PCR-based Hhal
digestion as described [18]. 
Loss of heterozygosity
Loss of heterozygosity was assessed by direct DNA
sequence analysis of tumour DNA for the presence or
absence of the wild-type allele. A normal control and
the constitutional DNA from the same person were
analysed on the same gel using identical chemistry. 
Immunohistochemistry of archival normal and tumour tissues
Expression of TP53 was assessed using the DO-7
antibody (DAKO, Copenhagen) on paraffin-embedded
normal and tumour tissues. A matching hematoxylin
and eosin (H+E) stained slide was used to determine
which parts of the sections were tumour tissue. Two
independent stains were done for every case. The
percentage of TP53 positive tumour nuclei was
determined, overexpression of the TP53 protein was
considered to be present if more than 15% of tumour
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nuclei at the invasion front were stained. Details of the
immunohistochemistry analysis and the evaluation
procedure are as described previously [28]. 
Statistical analysis
(2x2) tables were analysed using two-sided Fisher’s
exact test. Continuous variables were compared using
the Wilcoxon rank-sum test. Two-sided p values of 0.05
or less were considered significant. All results were
calculated using S-Plus 4.5 for Windows (Mathsoft Inc.,
Seattle, USA). 
Results
Intronic TP53 germline mutations in German breast/ovarian
cancer families
Fifty-one probands from 41 breast cancer families
and 7 breast-ovarian cancer families were studied for
germline mutations of the TP53 gene. Two different
intronic TP53 sequence variants were identified in five
breast cancer families and one breast-ovarian cancer
family (6/48, 12.5%). These included a novel 17708
A>T variant in intron 10 and a previously reported
13964 G>C variant in intron 6 [29]. Screening of all
coding exons of the TP53 gene did not reveal the
presence of additional mutations in any of the analysed
families. The characteristics of the families carrying
these variants are shown in Table 1. 
The 13964 G>C variant in intron 6 was identified in
families 19, 26, and P328. All carriers were heterozygous
for this mutation. In kindred 19, four females, of whom
three were diagnosed with breast cancer at 45, 45, and
49 years of age, respectively, and one with cancer of the
fallopian tube at 49 years of age, harboured the variant.
In kindred 26, four women carried the variant. Among
these, one woman was diagnosed with Hodgkin’s disease
and breast cancer at 22 and 34 years of age, respectively,
and one with breast cancer at 36 years of age. The
variant was inherited from the unaffected mother. One
aunt of the index patient, 60 years of age, harboured the
variant, whereas another one diagnosed with breast
cancer at 44 years of age did not. In kindred P328, one
woman diagnosed with breast cancer at 51 years of age
carried the variant, whereas one aunt on the paternal
side diagnosed with breast cancer at 67 years of age,
was negative. In addition to the TP53 sequence variant,
family P328 also harboured the Tyr179Cys missense
mutation in exon 8 of the BRCA1 gene. Both women
affected by breast cancer harboured the BRCA1 missense
mutation. One female mutation carrier, 43 years of age,
was asymptomatic. The BRCA1 missense mutation was
not found in 140 control individuals indicating that it is
disease-causative. 
A novel 17708 A>T nucleotide change in intron 10
segregating with the disease was detected in breast
cancer families 89, 128 and P313. In family 89, four
variant carriers were identified, three by direct analysis
and one was shown to be an obligatory carrier. The
obligatory carrier was diagnosed with cervical cancer
at an unknown age and breast cancer at 40 years of
age. This patient’s mutation was present in both of her
daughters, one being diagnosed with breast cancer at
45 years of age and the other is currently unaffected at
the age of 40. Two aunts of the index patient were also
diagnosed with breast cancer, one being diagnosed
with breast cancer at the age of 49, and the other
diagnosed with breast cancer at 70 years of age but
Table 1. Characteristics and TP53 sequence variants in German breast/ovarian cancer families
Family No. of breast cancers No.  Other cancers (age at diagnosis) TP53 mutation
(age at diagnosis) of ovarian
cancers
19 6 (38,39,45,45,49,50) 2 Lung (<45), 2x liver, vulva, colon (39), fallopian tube (49) IVS6, 13964 G>C
26 3 (34,36,44) 0 Hodgkin’s disease (22) IVS6, 13964 G>C
P328 a 3 (34,51,67) 0 5x prostate (52,59,70,75, <84), skin (43) IVS6, 13964 G>C
89 5 (40,45,48,51,70) 0 Cervix, colon, cancer of unknown type IVS10, 17708 A>T
128 5 (30,45,52,53,64) b 0 Brain, stomach/lung IVS10, 17708 A>T
P313 3 (43, 47) c 0 Malignant melanoma (51), sarcoma (61) IVS10, 17708 A>T
a Family P328 also carries a Tyr179Cys missense mutation of the BRCA1 gene. This mutation was described 35 times previously to the BIC database (39). 
b Including a male breast cancer. 
c One patient’s age at diagnosis is unknown. 
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was negative for this variant. In family 128, three female
carriers, diagnosed with breast cancer at 30, 52, and
53 years of age were identified, two by direct analysis
and the third was shown to be an obligatory carrier.
This sequence variant was also detected in 5/112
(4.5%) healthy controls suggesting that it is
a polymorphism rather than a causative mutation. 
Tumour DNA which was available from the index
patient was analysed for loss of heterozygosity (LOH) at
TP53 using direct DNA sequencing analysis. DNA was
available from one 17708 A>T-associated breast tumour
from one patient of family P313. In this family two
females were diagnosed with breast cancer at 43 and
47 years of age, one male presented with a malignant
melanoma at 51 years of age and one male with
a sarcoma at 61 years of age (data not shown). The
tumour DNA showed loss of the wild-type TP53 allele
(Figure 1). 
Immunohistochemical analysis revealed a loss of
TP53 protein immunoreactivity in normal and tumour
tissues.
Association of the 13964 G>C mutation with sporadic 
breast cancer
To analyse whether the 13964 G>C variant is also
associated with sporadic breast cancer, 185 unselected
Fig. 1. Electropherograms showing the sequence of the reverse
strand of part of intron 10 with the 17708 A to T nucleotide change.
Top panel: constitutional DNA of a healthy control individual; middle
panel: constitutional DNA of breast cancer patient P313; bottom
panel: tumour DNA of patient P313
Table 2. Clinical, pathological and molecular parameters of breast tumours in 13964 G>C carriers
Patients Age at diagnosis Histologya UICCb stage, grade % of TP53 positively stained cell nucleic
of breast cancer of malignancy Tumour tissue/Normal tissue
Sporadic
R670 63 IDC IIIA, G3 100/0
R688 68 IDC I, G3 0/0
R728 59 IDC I, G3 0/0
R729 50 IDC IIA, G3 0/0
Familial
26/III: 1 34 IDC I, G2 not available
26/III: 2 36 IDC IIB, G3 0/0
P328/II: 5 67 IDC I, G3 0/0
P328/III: 5 51 IDC+ILC IIB, G2 0/0
a IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma.
b According to UICC (1997) [40]. 
c Nuclear expression of TP53 protein was assessed by immunohistochemistry.
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consecutive German breast cancer patients were
screened. Four sporadic breast cancer patients (2.2%)
were determined to harbour the 13964 G>C change
compared to three out of 48 (6.2%) hereditary breast
cancer patients (p=0.15; Fisher’s exact test). All
sporadic breast cancer patients carrying the variant had
a negative family history of breast and ovarian cancer
as ascertained by medical records and anamnestic
questioning. Two variant carriers had a positive family
history of other cancers, in one family a kidney cancer
occurred at 65 years of age and in the other family two
colon cancers and an oesophagus cancer occurred at
the ages of 37, 61 and 35, respectively. 
Clinical and pathological characteristics 
of 13964 G>C-associated breast tumours and TP53 expression
The clinical and pathological features of breast
tumours diagnosed in eight 13964 G>C variant
carriers are listed in Table 2. The median age of breast
cancer diagnosis was 43.5 years for the four hereditary
cases and 61 years for the four sporadic cases. This
difference was not statistically significant (p=0.34,
Wilcoxon rank sum test). Seven patients presented with
invasive ductal carcinoma (IDC) of high or intermediate
grade of malignancy, and one patient with IDC and
invasive lobular carcinoma (ILC) of grade 2. 
Immunohistochemical analysis of TP53 protein
expression displayed negative immunoreactivity in
normal and tumour tissues of three sporadic and three
hereditary breast cancer patients harbouring the 13964
G>C variant. Positive staining was detected in the
tumour tissue of one sporadic mutation carrier, whereas
the normal tissue stained negatively. 
Discussion
In this study we screened the complete coding
region of the TP53 gene in 48 German breast/ovarian
cancer families negative for mutations in the BRCA1
and BRCA2 genes. Using SSCP and DNA sequencing
analysis two different TP53 sequence variants, an A to
T nucleotide change at position 17708 in intron 10
and a G to C nucleotide change at position 13964 in
intron 6 were identified in five breast cancer families
and in one breast-ovarian cancer family. 
The 17708 A>T nucleotide change is novel and has
not previously been identified in other populations.
Cosegregation of this variant in families 89 and 128, loss
of the wild-type allele in a 17708 A>T-associated breast
tumour and the presence of the variant allele in healthy
controls suggest that this variant is a polymorphism that
may modify breast cancer risk. The negative TP53 protein
immunoreactivity displayed by this tumour suggests that
mechanisms other than those leading to protein
accumulation are involved in the inactivation of TP53
function. These results are consistent with those of Sjögren
et al, who showed that 33% of breast tumours with TP53
mutations identified by complementary DNA sequencing
did not show positive immunoreactivity [30]. 
Three German breast/ovarian cancer families
harboured the 13964 G>C variant in intron 6. This
variant has previously been reported by several
investigators. It has been identified in three out of 73
patients with both breast and ovarian cancers [29]. Due
to the lack of functional tests for TP53 protein activity,
it has been classified as a non functional polymorphism.
It was also detected in five out of 70 children with
possible radiation-induced thyroid tumours and in one
out of 30 healthy children from areas in Belarus [31].
Since the family history of those patients was not
available, no conclusion about an association of this
nucleotide change with inherited cancer predisposition
was possible. Recently, the 13964 G>C variant was
detected at an elevated frequency in familial breast
cancer patients from North America [18]. Using
immortalised lymphoblastoid cell lines derived from
13964 G>C variant carriers, the investigators showed
that the mutation is functionally active and results in an
inhibition of apoptosis and prolongation of cell survival
in vitro upon DNA damage in response to cisplatin,
suggesting that this mutation affects breast cancer risk.
However, strict segregation of this variant with the
disease has not been shown. 
The frequency of 13964 G>C variants in our study
was 6.2%. This frequency is similar to those previously
reported in familial breast cancer patients from Australia
[32], North America [18], and Poland [33] being 4.2%,
7.1%, and 10.7%, respectively. In contrast to the
American study in which no association of this variant
with sporadic disease was detected, we also identified
this variant in 2.2% of sporadic breast cancer patients
from Germany. This frequency is similar to that observed
in sporadic breast cancer patients from Australia which
was 3.5% [32]. The discrepancy of these results may
partially be explained by differences in the populations. 
The 13964 G>C variant did not segregate with
the disease in families 26 and P328 and hence may
be not disease-causative. The additional presence of
the commonly reported BRCA1 missense mutation
Tyr179Cys in the same family that segregated with the
disease and the absence of this mutation in healthy
control individuals suggest that the BRCA1 mutation
may be causative, whereas the TP53 variant is more
likely to act as a risk modifier. 
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In contrast to the report by Lehman (2000) showing
positive TP53 staining in all three 13964 G>C-associated
hereditary breast tumours [18], in our study six of the seven
13964 G>C-associated breast cancers did not stain for
TP53, and only one sporadic tumour stained positively.
These findings suggest that the 13964 G>C variant does
not appear to play a direct role in the stabilisation of the
TP53 wild-type protein resulting in its abnormal
accumulation. The mechanism by which this variant
influences breast cancer risk remains to be determined. 
Several other germline mutations in intron 6 have
been described. A 13961 G>A sequence variant was
identified in six affected members of a Li-Fraumeni
family, and in only one out of 184 healthy controls
[34]. Strong TP53 protein immunoreactivity was
detected in both normal and tumour tissues from all
patients. A base substitution of G by A in the MspI site
followed by an insertion of TG was identified in
a Li-Fraumeni family and not in 85 healthy controls
[35]. Whereas strong TP53 protein immunoreactivity
was detected in both normal and tumour tissues from
these patients, no aberrant mRNA expression was
detected. Further, various other mutations in the region
13487-13494 were reported [36, 37]. Taken together
these studies imply that intron 6 of the TP53 gene could
be a mutation hot spot. These nucleotide changes may
act via novel mechanisms of gene regulation that
appear to be important for tumour formation. The
presence of CpG-rich Alu repetitive element adjacent
to the 13964 G>C base change may explain the
frequency of the sequence variant at this site [38]. 
The identification of intronic sequence differences
that do not directly result in either an abnormal
accumulation of TP53 or loss of TP53 activity does not
rule out the possibility that one or both of these changes
influence disease development. The penetrance of these
changes may be low such that in family studies the actual
contribution of these changes may be modest but if
studied at the population level disease associations may
be more apparent. The identification of these changes
therefore warrants a population-based study to assess
the likelihood that both changes may be low risk
modifiers rather than overt causative changes. 
In conclusion, the identification of intronic changes
in the TP53 gene suggests that there is a relationship
between the presence of these changes and disease
risk. Overtly, no apparent change in protein function
can be determined from these changes suggesting that
more subtle affects are more likely to result in an
increased disease risk. 
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